



Consolidated Financial Results
for the First Quarter of the Fiscal Year Ending March 31, 2017
[Based on Japanese GAAP]

August 3, 2016

Name of Listed Company: Meiji Holdings Co., Ltd. Listed exchange: 1st Section, Tokyo Stock Exchange
Code Number: 2269 URL: www.meiji.com
Representative: Masahiko Matsuo, President and Representative Director
Inquiries: Jun Furuta, Member of the Board and Executive Officer, General Manager of PR&IR Dept.
Telephone: +81-3-3273-3917

Submission of quarterly report: August 9, 2016

Dividend payment commencement: -

Preparation of explanatory materials for quarterly financial results: Yes

Holding of a briefing on quarterly financial results: None

(Amounts are rounded down to the nearest million yen.)

1. Consolidated Financial Results for the First Three Months of the Fiscal Year Ending March 31, 2017

(April 1, 2016 to June 30, 2016)

(1) Consolidated operating results

(% of change from the previous fiscal year)

	Net Sales		Operating Income		Ordinary Income		Net income attributable to shareholders of parent company	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
First three months ended								
June 30, 2016	301,075	2.7	22,039	30.6	21,845	25.1	16,685	-25.0
June 30, 2015	293,188	7.1	16,871	57.1	17,467	55.7	22,240	201.3

(Note) Comprehensive income: First three months ended June 30, 2016: 10,431 million yen (-56.3%)
First three months ended June 30, 2015: 23,857 million yen (164.4%)

	Net Income per Share	Diluted Net Income per Share
First three months ended	Yen	Yen
June 30, 2016	113.34	—
June 30, 2015	151.05	—

* The Company conducted a two-for-one stock split on October 1, 2015. The indicated per-share net income amounts for FYE March 2015 and FYE March 2016 reflect this stock split.

(2) Consolidated financial position

	Total Assets	Net Assets	Equity Ratio	Net Assets per Share
	Millions of yen	Millions of yen	%	Yen
As of June 30, 2016	837,555	419,303	49.1	2,792.02
As of March 31, 2016	856,115	419,152	47.8	2,777.28

(Reference) Shareholders' equity: As of June 30, 2016: 411,041 million yen
As of March 31, 2016: 408,874 million yen

Disclaimer: These financial statements have been prepared in accordance with generally accepted accounting principles in Japan.

This English translation is prepared for the reader's convenience. When there are any discrepancies between the original Japanese version and English translation version, the original Japanese version always prevails.

2. Dividends

	Cash Dividends Per Share				
	1Q	2Q	3Q	Financial year end	Annual
Fiscal year ended (or ending)	Yen	Yen	Yen	Yen	Yen
March 31, 2016	—	55.00	—	62.50	—
March 31, 2017	—				
March 31, 2017 (Projected)		45.00	—	45.00	90.00

(Note) Amendment to projected dividends recently announced: No

* The Company conducted a two-for-one stock split on October 1, 2015. The indicated per-share dividend amount for the second quarter of FYE March 2016 does not reflect this stock split.

3. Forecasts of Consolidated Financial Results for the Fiscal Year Ending March 31, 2017

(April 1, 2016 to March 31, 2017)

(% of change from the previous fiscal year)

	Net Sales		Operating Income		Ordinary Income		Net Income attributable to shareholders of parent company		Net Income per Share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
1st half	606,000	2.3	32,500	-2.7	32,500	-8.6	23,500	-29.1	159.62
Full year	1,251,000	2.2	74,500	-4.2	74,200	-9.3	50,000	-20.1	339.63

(Note) Amendment to forecasts of consolidated financial results recently announced: No

*Notes

(1) Changes in significant subsidiaries during the current fiscal year under review

(Changes in subsidiaries affecting the scope of consolidation): None

(2) Application of specific accounting treatments in the preparation of quarterly consolidated financial statements: Yes

(Note) For details, refer to page 4 of “2. Summary Information (Notes) (3) Adoption of Special Accounting Methods for Preparation of Quarterly Consolidated Financial Statements.”

(3) Changes in accounting policy, changes in accounting estimates, restatements

1. Changes in accounting policy due to revisions of accounting standards: Yes

2. Other changes in accounting policy: None

3. Changes in accounting estimates: Yes

4. Restatements: None

(Note) For details, refer to page 4 of “2. Summary Information (Notes) (4) Changes in Accounting Policy, Changes in Accounting Estimates, and Retrospective Restatements.”

(4) Number of shares outstanding (common stock)

1. Number of shares outstanding at end of period (including treasury stock)	As of Jun. 30, 2016	152,683,400 shares	As of Mar. 31, 2016	152,683,400 shares
2. Number of treasury stock at end of period	As of Jun. 30, 2016	5,463,346 shares	As of Mar. 31, 2016	5,462,223 shares
3. Average number of shares during period	As of Jun. 30, 2016	147,220,506 shares	As of Jun. 30, 2015	147,235,044 shares

* The Company conducted a two-for-one stock split on October 1, 2015. The indicated number of shares outstanding (common stock) reflects this stock split.

* Indication regarding the implementation of financial review procedures

This financial results report is not subject to the review procedures prescribed by the Financial Instruments and Exchange Act. At the time of the disclosure of this financial results report, the review procedures prescribed by the Financial Instruments and Exchange Act had not been completed.

* Forward-looking statements and other special notes

(Notice concerning forward-looking statements)

The forward-looking statements described in this document, such as business forecasts, are based on information available at the time of the release of these materials and reasonable assumptions made by the Company, and do not represent a commitment from the Company that they will be achieved. For earnings forecasts assumptions and other related items, refer to page 4 of “1. Qualitative Information, (3) Explanation Concerning Forecasts for Consolidated Earnings

(Explanatory material for financial results)

Explanatory materials for financial results are disclosed through TDnet together with these financial statements. This information also is posted on our website on the same day.

1. Qualitative Information

(1) Explanation Concerning Operating Results

(Millions of yen)

First Three Months ended	Net Sales	Operating Income	Ordinary Income	Net income attributable to shareholders of parent company	Net Income per Share (Yen)
June 30, 2016	301,075	22,039	21,845	16,685	113.34
June 30, 2015	293,188	16,871	17,467	22,240	151.05
% of YoY Change	2.7	30.6	25.1	-25.0	—

The Japanese economy during the first three months of FYE March 2017 (April 1, 2016 to June 30, 2016) saw improvement in the employment environment. However, the future outlook for economic conditions is becoming more severe as stock and currency market instability and overseas economic slowdown have led to pessimism among businesses and consumers.

Amid such conditions, the Meiji Group entered the second year of STEP UP 17, the Group's Medium-Term Business Plan. Based on our core policy of accelerating growth and achieving further improvement in profitability, we promote our growth strategy aimed at increasing corporate value. These initiatives include strengthening priority businesses and taking on the challenge of future growth, improving profitability to withstand harsh economic environments, pursuing global expansion, and evolving our management system.

In the food segment, amid an uncertain economic trends and the consumer environment, we continue selection and concentration strategy and structural reforms based on the core themes outlined in STEP UP 17 in order to achieve stable growth.

In the pharmaceuticals segment, there are concerns that NHI drug price revisions will have a significant impact on our earnings. Amid such conditions, in addition to our core domains of infectious disease drugs and central nervous system agents, and our lineup of generic drugs, we enhance activities to promote new drugs while also continuing to promote cost reductions in order to secure profits.

These factors resulted in net sales of 301,075 million yen (up 2.7%, year on year), operating income of 22,039 million yen (up 30.6%, year on year), ordinary income of 21,845 million yen (up 25.1%, year on year) during the first three month of FYE March 2017. Net income attributable to shareholders of parent company was 16,685 million yen (down 25.0%, year on year). This reflects the reverse effect of having recorded extraordinary income from gains on sales related to the transfer of fixed assets during the same quarter of the previous year.

Below is an overview by segment.

(Millions of yen)

	Reporting Segments			Adjustments	Amount Presented in Consolidated Statements of Income
	Food	Pharmaceuticals	Total		
Net Sales	267,676	33,716	301,392	-317	301,075
Operating Income	22,011	16	22,027	12	22,039

(i) Food segment

(Millions of yen)

	First three months of FYE March 2016 (from Apr. 1, 2015 to Jun.30, 2015)	First three months of FYE March 2017 (from Apr. 1, 2016 to Jun.30, 2016)	% of YoY Change
Net Sales	255,768	267,676	4.7
Operating Income	14,352	22,011	53.4

Net sales increased year on year. Net sales of the fresh and fermented dairy business, confectionery business, nutrition business, and other business increased year on year. Net sales of processed food business decreased year on year due to SKU reduction.

Operating income increased significantly year on year. In addition to expanding sales of mainstay products, we worked to improve our product mix, optimize production, and conducted other initiatives related to structural reforms and efficient budget allocation.

Below is an overview of each of this segment's main businesses.

- Fresh and Fermented Dairy business (Yogurt, drinking milk, beverages, etc.)
 - Net sales of functional yogurt increased significantly year on year. Net sales of *Meiji Probio Yogurt R-1* and *Meiji Probio Yogurt LG21* increased significantly thanks to aggressive advertising campaigns and efforts to create more appealing storefront displays.
 - Net sales of *Meiji Bulgaria Yogurt* increased significantly year on year. Net sales of our mainstay Plain yogurt drove overall brand sales thanks to strengthened aggressive advertising campaigns and promoted consumption opportunities resulting from the diversification of eating styles.
 - Net sales of drinking milk decreased year on year. Net sales of our mainstay product *Meiji Oishii Gyunyu* increased year on year due to the continuous efforts to promote the product as an ingredient for cooking.
- Processed Food business (Cheese, butter and margarine, cream, ice cream, frozen food, etc.)
 - Net sales of cheese increased significantly year on year due to the favorable sales of both natural and processed cheese. *Meiji Hokkaido Tokachi* series increased year on year thanks to the strong growth of camembert cheese. Net sales of *Meiji Saite Oishii Mozzarella*, released in March 2016, also grew significantly.
 - Net sales of margarine significantly decreased year on year due to the market decline.
 - Net sales of ice cream were largely unchanged year on year thanks to firm sales of our mainstay *Meiji Essel Super Cup*.
 - Net sales of frozen food decreased year on year. Gratin increased significantly year on year thanks to contributions from new products but net sales of pizza decreased year on year.
- Confectionery business (Chocolate, gummy, chewing gum, etc.)
 - Net sales of chocolate increased year on year. Net sales of the *Chocolate Kouka* series and other health-conscious chocolates significantly increased year on year. This was the result of increased interest in cocoa polyphenols and cocoa protein, in addition to expanded media exposure.
 - Net sales of gummy products significantly increased year on year. Our mainstay brand *Kaju Gummy* and *Poifull* grew significantly.
 - Net sales of chewing gum increased year on year amid continuing market decline.
- Nutrition business (Sports nutrition, infant formula, enteral formula, beauty supplement, OTC drugs, etc.)
 - Net sales of sports nutrition increased significantly year on year. Net sales of *SAVAS* increased significantly year on year. This was thanks to the benefits of promotional activities targeting athletes who demand performance and we captured more of the market for new protein users whose interests revolve around building a healthy body.
 - In the beauty supplement, net sales of *Amino Collagen* decreased significantly year on year due to decreased inbound demand.
 - Net sales of infant formula increased significantly year on year due to the continuous inbound demand.
 - Net sales of enteral formula increased significantly year on year. In particular, net sales of *Meiji Mei Balance Mini-cup* for the consumer market increased significantly thanks to efforts to create more appealing storefront displays and enhanced promotional activities.

■ Other business (International, food stuffs, livestock products, sugar and corn sweeteners, transportation, etc.)

International

- Among exports, net sales of infant formula to Taiwan and Pakistan increased significantly year on year. Also, in June 2016 we resumed sales of infant formula for the Vietnam market.
- Net sales in each business in China increased significantly year on year. In the confectionery business, sales of chocolate for wedding gift and export to Southeast Asia both grew. The drinking milk and yogurt business expanded its sales area and increased the number of stores handling commercial products for professional use. The ice cream business strengthened marketing strategies.
- Net sales in the U.S.A. increased year on year due to favorable growth of *Hello Panda*.

Others

- Net sales at domestic subsidiaries increased year on year due to expansion of the distribution business.

(ii) Pharmaceuticals segment

(Millions of yen)

	First three months of FYE March 2016 (from Apr. 1, 2015 to Jun.30, 2015)	For the Fiscal year ended March 31, 2017 (from Apr. 1, 2016 to Jun.30, 2016)	% of YoY Change
Net Sales	37,687	33,716	-10.5
Operating Income	2,583	16	-99.4

Net sales decreased significantly year on year. Net sales of domestic ethical pharmaceuticals business decreased year on year due to the impact of NHI drug price revisions. Net sales in the agricultural chemicals and veterinary drugs business decreased significantly year on year.

Operating income decreased significantly year on year due to declines in revenue from each business.

Below is an overview of each of this segment's main businesses.

■ Ethical Pharmaceuticals

Japan

- Net sales of the antibacterial drug *MEIACT* and *ORAPENAM* decline significantly year on year.
- Net sales of the antidepressant drug *REFLEX* increased significantly year on year due to aggressive promotional activities by medical representatives. The schizophrenia drug *SYCREST* launched in May 2016.
- Net sales of generic drugs decreased year on year. The antibacterial drug *TAZOPIPE Combination for I.V. Infusion Meiji* launched in December 2015 performed favorably. Our mainstay calcium channel blocker, *AMLODIPINE Tablets Meiji* and *DONEPEZIL Meiji*, a drug for Alzheimer's disease decreased significantly year on year.

International

- Among exports, net sales of our mainstay *MEIACT* decreased significantly year on year due to the impact of foreign exchange rates.
- Among international subsidiaries, businesses in Indonesia and Thailand performed favorably.

■ Agricultural chemicals and veterinary drugs

- Net sales of agricultural chemicals decreased significantly year on year. Sales of herbicide *ZAXA* increased year on year. Sales of rice blast preventative *ORYZEMATE* decreased year on year.
- Net sales of veterinary drugs decreased year on year. Net sales of marine chemicals increased significantly year on year. Net sales of livestock drugs decreased year on year, and drugs for companion animals decreased significantly year on year.

(2) Explanation Concerning Financial Status

[Assets]

For the three months of FYE March 2017, total assets decreased year by year by 18,560 million to 837,555 million yen. Although construction in progress increased by 4,380 million yen, cash and deposit, notes and accounts receivable, and investment securities decreased by 9,525 million yen, 10,222 million yen, and 3,022 million yen respectively.

[Liabilities]

For the three months of FYE March 2017, total liabilities decreased year by year by 18,711 million to 418,251 million yen. Although notes and accounts payable and short-term bank loans increased by 2,545 million yen and 9,910 million yen, respectively, income taxes payable, accrued bonuses for employees, and other current liabilities decreased by 16,147 million yen, 4,862 million yen, and 9,000 million yen, respectively.

[Net Assets]

For the three months of FYE March 2017, total net assets increased year by year by 151 million to 419,303 million yen. Although net unrealized holding gain or losses on securities and foreign currency translation adjustment decreased by 2,218 million yen and 4,705 million yen, respectively, retained earnings increased by 7,510 million yen.

Our equity ratio increased from 47.8% as of the previous consolidated accounting period to 49.1%.

(3) Explanation Concerning Forecasts for Consolidated Earnings

There are no changes to the consolidated earnings forecast in the “Consolidate Financial Results for the Fiscal Year Ended March 31, 2016” released on May 11, 2016.

2. Summary Information (Notes)

(1) Transfer of Significant Subsidiaries during the Current Quarter under Review

Not applicable.

(2) Changes in scope of consolidation or changes in the scope of application of the equity method

As of the first three months of FYE March 2017, Shikoku Meiji Dairy Products Co., Ltd., which was a consolidated subsidiary of Meiji Co., Ltd., merged with Shikoku Meiji Co., Ltd. The former Shikoku Meiji Dairy Products Co., Ltd. remains as the surviving company and its name changed to Shikoku Meiji Co., Ltd. As a result, the former Shikoku Meiji Co., Ltd. was eliminated and removed from the scope of consolidation.

As of the first three months of FYE March 2017, Shantou Meiji Pharmaceuticals Co., Ltd. and Guangdong Meiji Pharmaceutical Co., Ltd. were added to the scope of consolidation due to their increased importance.

(3) Adoption of Special Accounting Methods for Preparation of Quarterly Consolidated Financial Statements

Tax expenses are calculated by rationally estimating the effective tax rate after application of tax effect accounting to income before income taxes for the consolidated fiscal year, which includes the current quarter under review, then multiplying income before income taxes by the estimated effective tax rate.

Income taxes-deferred are shown included in income taxes.

(4) Changes in Accounting Policy, Changes in Accounting Estimates, and Retrospective Restatements

Changes in Accounting Policy

(Practical Solution Concerning Changes in Depreciation Methods Subsequent to FY2016 Tax Revisions)

Incidental to revisions to the Corporation Tax Act, Meiji Holdings and certain domestic consolidated subsidiaries applied “Practical Solution Concerning Changes in Depreciation Methods Subsequent to FY2016 Tax Revisions” (Practical Issues Task Force No. 32, June 17, 2016) beginning from the first three months of FYE March 2017. As a result, the depreciation method for buildings and accompanying facilities and structures acquired after April 1, 2016 was switched from the declining balance method to the straight line method.

The impact of this change on quarterly consolidated financial statements for the first three months of FYE March 2017 is minor.

Change in Accounting Estimates

(Change in service life years)

During the fiscal year ended March 2017, the future service life was reduced for buildings (including accompanying facilities) and structures held by Meiji Co., Ltd. with no expected use as a result of the relocation of its headquarters and research centers.

As a result of the change, compared to previous methods, operating income, ordinary income, and income before income taxes and minority interests declined by 390 million yen, respectively.

(5) Additional information

(Application of guidance concerning the recoverability of deferred tax assets)

“ASBJ Guidance Concerning the Recoverability of Deferred Tax Assets” (ASBJ Guidance No. 26, March 28, 2016) are applied from the first three months of FYE March 2017.

3. Quarterly Consolidated Financial Statements

(1) Quarterly Consolidated Balance Sheets

(Millions of yen)

	As of March 31, 2016	As of June 30, 2016
ASSETS		
Current assets		
Cash and deposits	31,883	22,358
Notes and accounts receivable	181,493	171,271
Goods and products	80,729	82,542
Work in process	3,365	4,964
Raw materials and supplies	39,509	41,531
Others	26,361	27,934
Allowance for doubtful accounts	-423	-384
Total current assets	362,919	350,217
Fixed assets		
Property, plants and equipment		
Buildings and structures	292,439	292,515
Less accumulated depreciation	-166,333	-167,886
Buildings and structures (net)	126,106	124,629
Machinery and equipment	495,891	495,297
Less accumulated depreciation	-367,186	-369,155
Machinery and equipment (net)	128,705	126,141
Tools and furniture	52,076	52,205
Less accumulated depreciation	-43,161	-43,219
Tools and furniture (net)	8,915	8,985
Land	72,837	72,232
Lease assets	4,833	4,695
Less accumulated depreciation	-3,605	-3,619
Lease assets (net)	1,228	1,076
Construction in progress	11,522	15,903
Total property, plants and equipment	349,314	348,968
Intangible assets		
Goodwill	14,560	12,918
Other	14,539	13,380
Total intangible assets	29,100	26,298
Investments and other fixed assets		
Investment securities	80,234	77,212
Other	34,729	35,011
Allowance for doubtful accounts	-183	-153
Total investments and other fixed assets	114,781	112,070
Total fixed assets	493,196	487,337
Total assets	856,115	837,555

(Millions of yen)

	As of March 31, 2016	As of June 30, 2016
LIABILITIES		
Current liabilities		
Notes and accounts payable	104,006	106,551
Short-term bank loans	29,831	39,742
Current portion of bonds	20,000	20,000
Income taxes payable	25,090	8,943
Accrued bonuses for employees	10,233	5,370
Allowance for sales returns	207	125
Allowance for sales rebates	1,892	1,851
Other current liabilities	85,434	76,434
Total current liabilities	276,696	259,020
Long-term liabilities		
Bonds	30,000	30,000
Long-term debt	67,997	67,461
Reserve for directors' retirement benefits	161	136
Retirement benefit liabilities	49,029	49,125
Other long-term liabilities	13,077	12,507
Total long-term liabilities	160,266	159,230
Total liabilities	436,963	418,251
NET ASSETS		
Shareholders' equity		
Common stock	30,000	30,000
Capital surplus	98,502	99,596
Retained earnings	277,869	285,380
Treasury stock, at cost	-9,727	-9,737
Total shareholders' equity	396,645	405,239
Accumulated other comprehensive income		
Net unrealized holding gains or losses on securities	26,417	24,198
Deferred gains or losses on hedges	8	-201
Foreign currency translation adjustments	3,137	-1,567
Adjusted cumulative of retirement benefits	-17,334	-16,626
Total accumulated other comprehensive income	12,229	5,802
Minority interests	10,278	8,262
Total net assets	419,152	419,303
Total liabilities and net assets	856,115	837,555

(2) Quarterly Consolidated Statements of Income and Consolidated Statements of Comprehensive Income
(Quarterly Consolidated Statements of Income)
(For the First Three Months Ended June 30, 2016)

(Millions of yen)

	First three months of FYE March 2016 (from Apr. 1, 2015 to Jun.30, 2015)	First three months of FYE March 2017 (from Apr. 1, 2016 to Jun.30, 2016)
Net sales	293,188	301,075
Cost of sales	188,533	191,278
Gross profit	104,655	109,796
Selling, general and administrative expenses	87,784	87,756
Operating income	16,871	22,039
Non-operating income		
Interest income	31	28
Dividend income	577	578
Rent income on fixed assets	144	35
Equity in income of affiliates	75	28
Other	278	235
Total non-operating income	1,105	906
Non-operating expenses		
Interest expenses	259	211
Foreign exchange losses	38	664
Rent cost of real estate	65	15
Other	145	209
Total non-operating expenses	508	1,100
Ordinary income	17,467	21,845
Extraordinary income		
Gain on sale of property, plants and equipment	17,657	5,062
Other	48	227
Total extraordinary income	17,705	5,289
Extraordinary losses		
Loss on disposal of property, plants and equipment	466	364
Impairment loss	829	–
Other	280	44
Total extraordinary losses	1,576	408
Income before income taxes	33,597	26,726
Income taxes-total	11,152	9,772
Net income	22,444	16,953
Net income or net losses attributable to non-controlling shareholders	204	267
Net income attributable to shareholders of parent company	22,240	16,685

(Quarterly Consolidated Statements of Comprehensive Income)
(For the First Three Months Ended June 30, 2016)

(Millions of yen)

	First three months of FYE March 2016 <small>(from Apr. 1, 2015 to Jun.30, 2015)</small>	First three months of FYE March 2017 <small>(from Apr. 1, 2016 to Jun.30, 2016)</small>
Net income	22,444	16,953
Other comprehensive income		
Net unrealized holding gains or losses on securities	1,232	-2,213
Deferred gains or losses on hedges	-6	-215
Foreign currency translation adjustments	-467	-4,520
Adjustments related to retirement benefits	632	707
Equity in affiliates accounted for by equity method	21	-280
Total other comprehensive income	1,412	-6,521
Comprehensive income	23,857	10,431
(Breakdown)		
Comprehensive income attributable to shareholders of parent company	23,754	10,259
Comprehensive income attributable to minority shareholders	103	172

(3) Notes Concerning Quarterly Financial Statements

(Notes Concerning the Premise of a Going Concern)

Not applicable.

(Notes Concerning Significant Changes in Shareholders' Equity (if any))

Not applicable.

(Segment Information, etc.)

Segment Information

I. The First Three Months of the Previous Consolidated Fiscal Year (April 1, 2015 to June 30, 2015)

1. Information on amounts of sales and income/losses for each reporting segment

(Millions of yen)

	Reporting Segments		Total	Adjustments (Note 1)	Amount Presented in Statements of Income (Note 2)
	Food	Pharmaceuticals			
Net Sales					
(1) Sales to Outside Customers	255,660	37,528	293,188	–	293,188
(2) Inter-segment Sales and Transfers	108	159	268	-268	–
Total	255,768	37,687	293,456	-268	293,188
Income by Segment	14,352	2,583	16,935	-64	16,871

(Notes)

1. Details of Adjustments are as follows:

The segment income adjustment of a negative 64 million yen includes inter-segment eliminations of 14 million yen and a negative 78 million yen in corporate expenses that are not allocated to individual reporting segments. Corporate expenses mainly consist of administrative expenses for the Company (the holding company).

2. Segment income is adjusted to the operating income recorded in the quarterly consolidated statements of income.

2. Information on impairment loss on fixed assets or good will, etc., for each reporting segment

(Significant impairment loss on fixed assets)

There was no significant impairment loss on fixed assets.

(Significant changes in the amount of goodwill)

There were no significant changes in the amount of goodwill.

(Significant gain on negative goodwill)

No significant negative goodwill was generated.

II The First Three Months of the Consolidated Fiscal Year under Review (April 1, 2016 to June 30, 2016)

1. Information on amounts of sales and income/losses for each reporting segment

(Millions of yen)

	Reporting Segments		Total	Adjustments (Note 1)	Amount Presented in Statements of Income (Note 2)
	Food	Pharmaceuticals			
Net Sales					
(1) Sales to Outside Customers	267,596	33,478	301,075	–	301,075
(2) Inter-segment Sales and Transfers	79	237	317	-317	–
Total	267,676	33,716	301,392	-317	301,075
Income by Segment	22,011	16	22,027	12	22,039

(Notes)

1. Details of Adjustments are as follows:

The segment income adjustment of 12 million yen includes inter-segment eliminations of 53 million yen and a negative 41 million yen in corporate expenses that are not allocated to individual reporting segments. Corporate expenses mainly consist of administrative expenses for the Company (the holding company).

2. Segment income is adjusted to the operating income recorded in the quarterly consolidated statements of income.

2. Information concerning changes in reporting segments, etc.

(Practical Solution Concerning Changes in Depreciation Methods Subsequent to FY2016 Tax Revisions)

As indicated in Changes in Accounting Policy, Incidental to revisions to the Corporation Tax Act, Meiji Holdings and certain domestic consolidated subsidiaries applied “Practical Solution Concerning Changes in Depreciation Methods Subsequent to FY2016 Tax Revisions” beginning from the first three months of FYE March 2017. As a result, the depreciation method for buildings and accompanying facilities and structures acquired after April 1, 2016 was switched from the declining balance method to the straight line method. The impact of this change on quarterly consolidated financial statements for the first three months of FYE March 2017 is minor.

(Change in service life years)

As indicated in Change in accounting estimates, during the fiscal year ended March 2017, the future service life was reduced for buildings (including accompanying facilities) and structures held by Meiji Co., Ltd. with no expected use as a result of the relocation of its headquarters and research center.

As a result of the change, compared to previous methods, segment income in the food segment declined by 390 million yen.

3. Information on impairment loss on fixed assets or good will, etc., for each reporting segment

(Significant impairment loss on fixed assets)

There was no significant impairment loss on fixed assets.

(Significant changes in the amount of goodwill)

There were no significant changes in the amount of goodwill.

(Significant gain on negative goodwill)

No significant negative goodwill was generated.

(Significant Subsequent Events)

Not applicable.

Consolidated Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2017

- Supplementary Explanatory Data -

Contents

1. Consolidated Financial Results	1
2. Segment Information	4
3. Analysis of Operating Income	6
4. Consolidated Financial Positions	7
5. Capital Expenditures, Depreciation, R&D Expenses	8
6. Financial Indicators, consolidated	8
7. Sales by Main Products	9
8. Other	
1. (Ref.) Net Sales of Exports and Foreign Consolidated Group Companies	11
2. List of New Products Under Development	11

meiji

Meiji Holdings Co., Ltd.

*This document has been translated from the original Japanese as a guide for non-Japanese investors.

*Unaudited figures are included in these materials for reference.

*The forward-looking statements described in this document, such as business forecasts, are based on information available at the time of the release of this presentation and reasonable assumptions made by the Company, and do not represent a commitment from the Company that they will be achieved.

*Unless otherwise stated, figures for plan indicated in these materials are fiscal year initial targets announced on May 11, 2016.

(Amounts appearing in the tables below have been rounded down to nearest 100 million yen)

1. Consolidated Financial Results

1. Consolidated Operating Results

(Billions of yen)

FYE March 2017	Q1		Q1-Q2		Q1-Q3		Full-year	
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan
Net sales	301.0	+2.7	49.7					
Cost of sales	191.2	+1.5	—					
Gross profit	109.7	+4.9	—					
Selling, general and administrative expenses	87.7	-0.0	—					
Carriage and storage charges	11.9	+0.6	—					
Sales promotion expenses	32.3	-2.6	—					
Labor cost	19.5	-0.3	—					
Operating income	22.0	+30.6	67.8					
Ordinary income	21.8	+25.1	67.2					
Net income attributable to owners of parent	16.6	-25.0	71.0					

Plan -- FYE March 2017					
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
606.0	+2.3	645.0	+2.1	1,251.0	+2.2
—	—	—	—	—	—
—	—	—	—	—	—
—	—	—	—	—	—
—	—	—	—	—	—
—	—	—	—	—	—
32.5	-2.7	42.0	-5.4	74.5	-4.2
32.5	-8.6	41.7	-9.9	74.2	-9.3
23.5	-29.1	26.5	-10.0	50.0	-20.1

FYE March 2016	Q1		Q1-Q2		Q1-Q3		Full-year	
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan
Net sales	293.1	+7.1	49.7	+5.9	+0.4	914.3	+5.2	75.7
Cost of sales	188.5	+4.3	—	+3.0	—	584.4	+3.2	—
Gross profit	104.6	+12.7	—	+11.5	—	329.8	+9.1	—
Selling, general and administrative expenses	87.7	+6.9	—	+4.4	—	270.5	+4.4	—
Carriage and storage charges	11.9	+18.2	—	+12.6	—	35.6	+11.4	—
Sales promotion expenses	33.2	+8.9	—	+5.7	—	104.0	+4.6	—
Labor cost	19.5	+3.1	—	+3.0	—	58.7	+3.4	—
Operating income	16.8	+57.1	62.5	+76.0	+23.7	59.2	+38.1	89.2
Ordinary income	17.4	+55.7	60.2	+80.7	+22.6	62.4	+38.7	90.5
Net income attributable to owners of parent	22.2	+201.3	75.4	+163.0	+12.3	51.2	+73.2	95.7

Results -- FYE March 2016					
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
592.3	+5.9	631.4	+4.9	1,223.7	+5.4
380.9	+3.0	397.2	+2.4	778.1	+2.7
211.3	+11.5	234.1	+9.5	445.5	+10.5
177.9	+4.4	189.7	+4.7	367.7	+4.5
24.1	+12.6	22.8	+10.5	46.9	+11.6
67.5	+5.7	74.8	+6.7	142.4	+6.2
39.0	+3.0	39.3	+1.9	78.4	+2.4
33.4	+76.0	44.3	+36.3	77.7	+50.9
35.5	+80.7	46.2	+36.5	81.8	+52.7
33.1	+163.0	29.4	+61.0	62.5	+102.6

2. Operating Results of Food Segment

(Billions of yen)

FYE March 2017	Q1		Q1-Q2		Q1-Q3		Full-year	
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan
Net sales	267.6	+4.7	50.6					
Cost of sales	174.9	+2.3	—					
Gross profit	92.6	+9.3	—					
Selling, general and administrative expenses	70.6	+0.3	—					
Carriage and storage charges	11.5	+0.9	—					
Sales promotion expenses	28.6	-2.4	—					
Labor cost	13.8	-0.6	—					
Operating income	22.0	+53.4	71.0					
Ordinary income	21.7	+49.6	69.6					
Net income attributable to owners of parent	16.7	+83.7	72.7					

Plan -- FYE March 2017					
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
529.5	+2.4	543.5	-0.1	1,073.0	+1.1
—	—	—	—	—	—
—	—	—	—	—	—
—	—	—	—	—	—
—	—	—	—	—	—
31.0	+7.9	34.0	-14.0	65.0	-4.8
31.3	+2.2	34.1	-16.0	65.4	-8.1
23.0	+20.6	22.7	-17.1	45.7	-1.6

FYE March 2016	Q1		Q1-Q2		Q1-Q3		Full-year	
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan
Net sales	255.7	+3.7	49.7		795.9	+3.2	76.2	
Cost of sales	170.9	+1.1	—		528.4	+0.6	—	
Gross profit	84.7	+9.2	—		267.5	+8.9	—	
Selling, general and administrative expenses	70.4	+3.9	—		216.5	+1.5	—	
Carriage and storage charges	11.4	+18.0	—		34.3	+11.2	—	
Sales promotion expenses	29.3	+7.1	—		91.6	+2.4	—	
Labor cost	13.9	+0.7	—		41.8	+1.5	—	
Operating income	14.3	+45.8	58.1		50.9	+57.5	94.3	
Ordinary income	14.5	+46.6	54.6		53.0	+58.9	94.8	
Net income attributable to owners of parent	9.0	+40.3	52.3		34.1	+59.8	97.0	

Results -- FYE March 2016					
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
517.1	+2.7	544.2	+5.0	1,061.3	+3.9
345.6	+0.1	355.0	+1.3	700.6	+0.7
171.4	+8.4	189.2	+12.7	360.7	+10.6
142.7	+1.4	149.7	+4.2	292.4	+2.8
23.2	+12.5	21.9	+11.0	45.1	+11.8
59.5	+2.6	65.1	+6.7	124.7	+4.7
27.7	+0.8	28.0	+0.7	55.7	+0.8
28.7	+64.9	39.5	+63.2	68.2	+63.9
30.6	+72.7	40.5	+57.4	71.2	+63.6
19.0	+75.9	27.3	+95.3	46.4	+86.8

3. Operating Results of Pharmaceuticals Segment

(Billions of yen)

FYE March 2017	Q1		Q1-Q2		Q1-Q3		Full-year	
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan
Net sales	33.7	% -10.5	% 43.6	%	%	%	%	%
Cost of sales	16.5	-6.5	—					
Gross profit	17.1	-14.1	—					
Selling, general and administrative expenses	17.1	-1.4	—					
Operating income	0.0	-99.4	0.9					
Ordinary income	-0.3	—	—					
Net income attributable to owners of parent	-0.3	—	—					

Plan -- FYE March 2017					
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
77.3	% +1.5	102.5	% +16.0	179.8	% +9.3
—	—	—	—	—	—
—	—	—	—	—	—
1.8	-63.6	8.2	+58.7	10.0	-1.2
1.2	-74.7	7.6	+27.2	8.8	-18.0
0.3	-88.0	4.1	+54.7	4.4	-14.6

FYE March 2016	Q1		Q1-Q2		Q1-Q3		Full-year					
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan				
Net sales	37.6	% +38.4	% 49.4	% 76.1	% +34.1	% -0.1	% 120.1	% +20.7	% 72.2	% 164.5	% +16.4	% -1.1
Cost of sales	17.7	+48.6	—	36.0	+42.7	—	57.4	+34.8	—	79.3	+24.4	—
Gross profit	19.9	+30.4	—	40.0	+27.2	—	62.6	+10.2	—	85.2	+9.8	—
Selling, general and administrative expenses	17.3	+20.1	—	35.1	+17.4	—	53.7	+16.6	—	75.1	+11.2	—
Operating income	2.5	+209.3	114.9	4.9	+212.4	+120.2	8.8	-17.2	69.9	10.1	+0.4	-20.3
Ordinary income	2.5	+202.1	126.8	4.7	+212.5	+138.9	9.5	-12.5	71.8	10.7	+4.3	-19.3
Net income attributable to owners of parent	1.4	+139.8	228.0	2.5	+142.6	+301.9	5.7	-21.2	77.9	5.1	-5.0	-30.4

Results -- FYE March 2016					
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
76.1	% +34.1	88.3	% +4.5	164.5	% +16.4
36.0	+42.7	43.2	+12.4	79.3	+24.4
40.0	+27.2	45.1	-2.1	85.2	+9.8
35.1	+17.4	39.9	+6.3	75.1	+11.2
4.9	+212.4	5.1	-39.1	10.1	+0.4
4.7	+212.5	5.9	-31.8	10.7	+4.3
2.5	+142.6	2.6	-39.7	5.1	-5.0

2. Segment Information

1. Food Segment

A. Net Sales

(Billions of yen)

FYE March 2017	Q1		Q1-Q2		Q1-Q3		Full-year	
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan
Fresh and Fermented Dairy	136.7	+9.4	53.7					
Processed Food	45.0	-6.4	48.8					
Confectionery	36.0	+3.0	51.2					
Nutrition	23.8	+0.0	47.7					
Other	88.2	+5.7	49.0					
Elimination	-62.3	—	—					

Plan -- FYE March 2017					
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
254.5	+2.4	253.4	-3.7	508.0	-0.7
92.3	-6.2	87.1	-6.5	179.4	-6.4
70.4	+0.4	93.3	+3.3	163.7	+2.0
50.0	+1.5	47.1	+1.6	97.1	+1.5
180.0	+5.1	182.4	+2.5	362.5	+3.8
-117.9	—	-120.0	—	-238.0	—

FYE March 2016	Q1		Q1-Q2		Q1-Q3		Full-year	
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan
Fresh and Fermented Dairy	125.0	+5.7	50.4	+4.1	+0.1	375.6	+4.5	77.9
Processed Food	48.1	+0.0	48.7	-1.3	-0.5	148.9	-1.7	77.3
Confectionery	34.9	-0.3	49.6	+0.2	-0.6	116.5	+0.1	73.4
Nutrition	23.8	+24.2	49.4	+16.4	+2.1	75.1	+13.8	80.0
Other	83.5	-0.6	49.3	+1.5	+1.1	263.8	+3.4	74.1
Elimination	-59.8	—	—	—	—	-184.1	—	—

Results -- FYE March 2016					
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
248.6	+4.1	263.0	+9.3	511.7	+6.7
98.5	-1.3	93.1	-1.7	191.6	-1.5
70.1	+0.2	90.3	+1.6	160.4	+1.0
49.3	+16.4	46.4	+8.0	95.7	+12.2
171.2	+1.5	178.1	+3.8	349.3	+2.6
-120.8	—	-126.8	—	-247.6	—

B. Operating Incomes

(Billions of yen)

FYE March 2017	Q1		Q1-Q2		Q1-Q3		Full-year	
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan
Fresh and Fermented Dairy	13.8	+50.5	71.8					
Processed Food	1.7	+24.5	46.3					
Confectionery	3.9	+124.6	126.3					
Nutrition	3.5	+44.2	55.6					
Other	1.0	+104.5	103.0					
Elimination and Corporate expenses	-2.1	—	—					

Plan -- FYE March 2017					
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
19.3	+9.1	20.7	-14.3	40.0	-4.4
3.7	+7.5	2.3	-8.6	6.0	+0.8
3.1	+18.0	9.7	-3.4	12.8	+1.1
6.4	+16.3	4.0	-2.2	10.5	+8.3
0.9	-16.9	2.1	+2.9	3.0	-4.4
-2.6	—	-4.9	—	-7.6	—

FYE March 2016	Q1		Q1-Q2		Q1-Q3		Full-year	
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan
Fresh and Fermented Dairy	9.2	+35.8	53.0	+34.1	+1.7	27.3	+33.1	82.8
Processed Food	1.4	+371.7	41.4	+114.3	+3.7	5.6	+81.5	101.4
Confectionery	1.7	-41.9	75.7	+0.9	+14.2	9.4	+25.1	98.7
Nutrition	2.4	+173.4	60.5	+125.4	+34.9	9.1	+104.6	117.4
Other	0.4	—	104.1	+2,973.5	+148.8	2.7	+480.0	105.9
Elimination and Corporate expenses	-1.0	—	—	-1.8	—	-3.4	—	-5.3

Results -- FYE March 2016					
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
17.7	+34.1	24.2	+60.1	41.9	+47.9
3.5	+114.3	2.5	+31.3	6.0	+69.6
2.6	+0.9	10.0	+46.8	12.7	+34.1
5.5	+125.4	4.1	+94.6	9.7	+111.0
1.1	+2,973.5	2.0	+453.1	3.2	+692.9
-1.8	—	-3.4	—	-5.3	—

Note1: As reference information for the Food segment, we have included results for each business category (simple calculation figures prior to elimination).

Note2: Eliminations within the Food segment include eliminations within each business category and between business categories. Also, general corporate expenses refer to expenses not allocated to any specific business.

2. Pharmaceuticals Segment

(Billions of yen)

FYE March 2017	Q1		Q1-Q2		Q1-Q3		Full-year	
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan
Ethical Pharmaceuticals	30.5	-10.4	43.6					
Agricultural Chemicals and Veterinary Drugs	3.1	-11.6	43.7					

Plan -- FYE March 2017					
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
	%		%		%
70.0	+1.2	87.5	+17.4	157.6	+9.6
7.3	+5.8	14.9	+8.1	22.2	+7.3

FYE March 2016	Q1		Q1-Q2		Q1-Q3		Full-year					
	YoY change	H1 plan achievement rate	YoY change	vs. H1 plan	YoY change	Full-year plan achievement rate	YoY change	vs. Full-year plan				
Ethical Pharmaceuticals	34.0	+38.7	49.5	69.2	+35.8	+0.5	109.4	+21.7	75.6	143.7	+18.0	-0.7
Agricultural Chemicals and Veterinary Drugs	3.6	+35.8	49.2	6.8	+19.5	-5.9	10.7	+11.5	49.6	20.7	+6.6	-3.9


Results -- FYE March 2016					
H1 (Q1-Q2)	YoY change	H2 (Q3-Q4)	YoY change	Full-year	YoY change
	%		%		%
69.2	+35.8	74.5	+5.2	143.7	+18.0
6.8	+19.5	13.8	+1.2	20.7	+6.6

3. Analysis of Operating Income

1. Results

(Billions of yen)

	Q1				Q1-Q2				Q1-Q3				Full-year			
	Consolidated Total	Food	Pharma	Other	Consolidated Total	Food	Pharma	Other	Consolidated Total	Food	Pharma	Other	Consolidated Total	Food	Pharma	Other
Results -- FYE March 2016	16.8	14.3	2.5	0.0												
Due to increased/decreased sales	+3.8	+3.9	-0.1	—												
Impact of drug price revision	-1.7	—	-1.7	—												
Changes in costs of goods sold	+2.1	+2.1	0.0	—												
Changes in other SG&A expenses	-0.2	+0.5	-0.7	—												
Other (incl. change in results of subsidiaries)	+1.2	+1.2	0.0	0.0												
Total change	+5.2	+7.7	-2.5	0.0												
Results -- FYE March 2017	22.0	22.0	0.0	0.0												



(Breakdown)

*1: [Food] Imported dairy ingredients: +0.7, Changes due to net content reduction of products and other cost reduction: +0.7
Production optimization: +0.4

*2: [Food] Decrease in sales promotion expenses: +0.9, Distribution optimization: +0.5, Other: -0.9
[Pharma] Decrease in R&D expenses: +0.2, Increase in promotion expenses: -0.4, Other: -0.5

2. Plan -- FYE March 2017

(Billions of yen)

	H1 (Q1-Q2)				H2 (Q3-Q4)				Full-year			
	Consolidated Total	Food	Pharma	Other	Consolidated Total	Food	Pharma	Other	Consolidated Total	Food	Pharma	Other
Results -- FYE March 2016	33.4	28.7	4.9	Δ0.2	44.3	39.5	5.1	-0.4	77.7	68.2	10.1	-0.6
Due to increased/decreased sales	+4.6	+1.9	+2.7	—	+6.6	-1.5	+8.1	—	+11.2	+0.4	+10.8	—
Impact of drug price revision	-4.2	—	-4.2	—	-5.0	—	-5.0	—	-9.2	—	-9.2	—
Changes in costs of goods sold	+1.1	+1.1	0.0	—	-0.5	-0.5	0.0	—	+0.6	+0.6	0.0	—
Changes in other SG&A expenses	-2.1	-0.4	-1.7	—	-2.8	-1.9	-0.9	—	-4.9	-2.3	-2.6	—
Other (incl. change in results of subsidiaries)	-0.3	-0.3	+0.1	-0.1	-0.6	-1.6	+0.8	+0.2	-0.9	-1.9	+0.9	+0.1
Total change	-0.9	+2.3	-3.1	-0.1	-2.3	-5.5	+3.0	+0.2	-3.2	-3.2	-0.1	+0.1
Plan -- FYE March 2017	32.5	31.0	1.8	-0.3	42.0	34.0	8.2	-0.2	74.5	65.0	10.0	-0.5

4. Consolidated Financial Positions

(Billions of yen)

FYE March 2017	As of Jun. 30		As of Sep. 30		As of Dec. 31		As of Mar. 31	
		Change from the previous fiscal year end		Change from the previous fiscal year end		Change from the previous fiscal year end		Change from the previous fiscal year end
Total assets	837.5	-2.2						
Current assets	350.2	-3.5						
Fixed assets	487.3	-1.2						
Total liabilities	418.2	-4.3						
Current liabilities	259.0	-6.4						
Long-term liabilities	159.2	-0.6						
Total net assets	419.3	+0.0						
Shareholders' equity	405.2	+2.2						
Reference	Consolidated interest bearing debt	157.2	+6.3					
	Food segment assets	589.3	-0.5					
	Pharmaceuticals segment assets	193.9	-3.3					

(Billions of yen)

FYE March 2016	As of Jun. 30		As of Sep. 30		As of Dec. 31		As of Mar. 31		
		Change from the previous fiscal year end		Change from the previous fiscal year end		Change from the previous fiscal year end		Change from the previous fiscal year end	
Total assets	860.6	-1.9	855.8	-2.4	899.8	+2.6	856.1	Δ2.4	
Current assets	350.3	-0.5	354.1	+0.6	385.3	+9.5	362.9	+3.1	
Fixed assets	510.2	-2.9	501.7	-4.5	514.5	-2.1	493.1	Δ6.1	
Total liabilities	461.1	-7.2	448.6	-9.7	474.2	-4.6	436.9	Δ12.1	
Current liabilities	261.2	-12.5	271.0	-9.2	308.6	+3.4	276.6	Δ7.3	
Long-term liabilities	199.8	+0.7	177.6	-10.5	165.6	-16.6	160.2	Δ19.3	
Total net assets	399.4	+5.0	407.1	+7.1	425.5	+11.9	419.1	+10.2	
Shareholders' equity	360.2	+5.2	371.2	+8.4	385.2	+12.5	396.6	+15.8	
Reference	Consolidated interest bearing debt	200.3	-9.5	179.6	-18.9	175.5	-20.7	147.8	Δ33.3
	Food segment assets	601.1	-0.1	610.4	+1.4	634.7	+5.4	592.1	Δ1.6
	Pharmaceuticals segment assets	200.3	-2.5	194.4	-5.3	205.1	-0.1	200.5	Δ2.4

5. Capital Expenditures, Depreciation, R&D Expenses

(Billions of yen)

	FYE March 2014		FYE March 2015		FYE March 2016		FYE March 2017- Plan	
	H1	Full-year	H1	Full-year	H1 (01-02)	Full-year	H1 (01-02)	Full-year
Capital expenditures	21.8	47.0	28.4	64.3	24.1	42.3	20.5	46.7
Food segment	18.8	41.5	24.9	55.8	21.2	36.5	16.0	39.4
Pharmaceutical segment	2.9	5.4	3.5	8.5	2.8	5.7	4.5	7.2
Corporate or elimination	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
Depreciation and amortization	19.8	40.9	19.9	41.8	19.7	42.0	20.9	42.7
Food segment	16.6	34.3	16.9	35.3	17.3	36.5	17.8	36.5
Pharmaceutical segment	2.5	5.4	2.4	5.4	2.2	5.3	3.0	6.0
Corporate or elimination	0.6	1.1	0.5	1.0	0.1	0.2	0.1	0.2
R&D expenses	12.3	26.0	11.9	26.1	12.9	27.3	12.7	26.5
Food segment	5.6	11.3	6.1	12.5	6.4	12.6	6.4	12.4
Pharmaceutical segment	6.7	14.7	5.7	13.5	6.5	14.6	6.3	14.1
Corporate or elimination	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

6. Financial Indicators, consolidated

	FYE March 2013	FYE March 2014	FYE March 2015	FYE March 2016	
	Full-year	Full-year	Full-year	Full-year	
Net sales	1,126.5 billion yen	1,148.0 billion yen	1,161.1 billion yen	1,223.7 billion yen	
Operating income	25.8 billion yen	36.4 billion yen	51.5 billion yen	77.7 billion yen	
Operating income ratio	2.3 %	3.2 %	4.4 %	6.4 %	
EBITDA	66.8 billion yen	77.6 billion yen	94.0 billion yen	121.6 billion yen	(Note) Op. income + Depreciation and amortization
EBITDA margin	5.9 %	6.8 %	8.1 %	9.9 %	
Net income attributable to shareholders of parent company	16.6 billion yen	19.0 billion yen	30.8 billion yen	62.5 billion yen	
Net income ratio	1.5 %	1.7 %	2.7 %	5.1 %	
Total assets	785.5 billion yen	779.4 billion yen	877.3 billion yen	856.1 billion yen	
Interest bearing debt	205.3 billion yen	198.3 billion yen	221.4 billion yen	147.8 billion yen	
Shareholders' equity	313.3 billion yen	320.4 billion yen	370.3 billion yen	408.8 billion yen	
Shareholders' equity ratio	39.9 %	41.1 %	42.2 %	47.8 %	
Debt/Equity ratio	0.7 %	0.6 %	0.6 %	0.4 %	
ROA	3.8 %	5.0 %	6.5 %	9.4 %	(Note) Ordinary income/Average net assets
ROE	5.5 %	6.0 %	8.9 %	16.1 %	(Note) Net income attributable to shareholders of parent company/Average shareholders' equity
Cash flows from operating activities	50.6 billion yen	63.8 billion yen	86.4 billion yen	105.1 billion yen	
Cash flows from investing activities	-39.5 billion yen	-47.2 billion yen	-92.8 billion yen	-9.8 billion yen	
Free cash flows	11.1 billion yen	16.5 billion yen	-6.3 billion yen	95.3 billion yen	(Note) Cash flows from operating activities + Cash flows from investing activities
Net income per share	112.99 yen	129.40 yen	209.79 yen	425.06 yen	(Note) Net income attributable to shareholders of parent company / (Number of shares outstanding - Number of treasury stock)
Net assets per share	2,127.28 yen	2,175.98 yen	2,515.26 yen	2,777.28 yen	(Note) (Total net assets - Noncontrolling interests) / (Number of shares outstanding - Number of treasury stock)
Cash flow per share	390.07 yen	407.55 yen	494.24 yen	710.89 yen	(Note) (Net income attributable to shareholders of parent company + Depreciation and Amortization) / (Number of shares outstanding - Number of treasury stock)
Cash dividends per share	40.00 yen	40.00 yen	50.00 yen	90.00 yen	
Dividend payout ratio	35.4 %	30.9 %	23.8 %	21.2 %	
Price/Earnings ratio--PER	19.3 times	25.2 times	34.9 times	21.3 times	(Note) Year-end stock price/Net income per share
Price/Book value ratio--PBR	1.0 times	1.5 times	2.9 times	3.3 times	(Note) Year-end stock price/Net assets per share
Price/Cash flow ratio--PCFR	5.6 times	8.0 times	14.8 times	12.7 times	(Note) Year-end stock price/Cash flow per share

Note: The above figures per share are calculated by retroactively applying the number of shares resulting from the stock split conducted on October 1, 2015.

7. Sales by Main Products

1. Food Segment (Non-consolidated)

(Billions of yen)

FYE March 2017	Q1		Q1-Q2			Q1-Q3			Full-year		
	YoY Change	H1 Plan Achievement Rate	YoY Change	vs. H1 Plan	YoY Change	Full-year Plan Achievement Rate	YoY Change	vs. Full-year Plan	YoY Change	vs. Full-year Plan	
	%	%	%	%	%	%	%	%	%	%	
Yogurt	23.3	+8.9	54.5								
Meiji Bulgaria Yogurt	21.7	+11.7	54.3								
Probiotic yogurts	28.3	+20.4	58.7								
Drinking milk	27.0	-1.9	49.7								
Meiji Oishii Gyunyu	14.5	+1.4	49.4								
Cheese	8.9	+8.7	53.7								
Meiji Hokkaido Tokachi series	3.2	+8.4	54.5								
Ice cream	13.2	-0.3	45.0								
Chocolate	20.7	+9.7	52.8								
Nutritional products ^(Note)	13.2	+9.4	51.6								
Sports nutrition	4.8	+12.6	48.6								

Plan -- FYE March 2017					
H1 (Q1-Q2)	YoY Change	H2 (Q3-Q4)	YoY Change	Full-year	YoY Change
%	%	%	%	%	%
42.8	+0.1	39.9	-1.0	82.8	-0.5
40.0	+2.7	37.5	+1.2	77.6	+2.0
48.2	+5.8	59.7	-2.3	108.0	+1.2
54.5	-2.8	49.6	-6.1	104.1	-4.4
29.5	-1.6	26.1	-4.8	55.6	-3.1
16.6	+2.1	18.3	-0.5	35.0	+0.7
5.9	+1.8	6.8	+1.8	12.8	+1.8
29.3	+1.3	16.9	-3.7	46.2	-0.6
39.2	+3.0	58.8	+2.2	98.0	+2.5
25.6	+3.7	26.5	+3.6	52.1	+3.7
10.0	+15.2	8.2	+10.5	18.3	+13.1

FYE March 2016	Q1		Q1-Q2			Q1-Q3			Full-year			
	YoY Change	H1 Plan Achievement Rate	YoY Change	vs. H1 Plan	YoY Change	Full-year Plan Achievement Rate	YoY Change	vs. Full-year Plan	YoY Change	vs. Full-year Plan		
	%	%	%	%	%	%	%	%	%	%		
Yogurt	21.4	+5.2	50.7	42.8	+6.4	+1.3	62.6	+6.1	78.8	83.1	+6.4	+4.6
Meiji Bulgaria Yogurt	19.4	+4.6	50.7	39.0	+6.0	+1.6	57.2	+6.0	79.8	76.1	+6.4	+6.2
Probiotic yogurts	23.5	+22.7	51.6	45.6	+17.0	+0.0	71.1	+15.6	72.9	106.7	+22.4	+9.5
Drinking milk	27.6	+1.4	49.8	56.1	+1.3	+1.3	83.3	+1.2	80.2	108.9	+1.5	+4.8
Meiji Oishii Gyunyu	14.3	+5.6	49.8	29.9	+4.6	+4.0	44.0	+4.4	79.3	57.4	+4.2	+3.5
Cheese	8.2	+1.3	50.5	16.3	+1.0	+0.1	26.2	+2.7	77.7	34.8	+3.1	+3.0
Meiji Hokkaido Tokachi series	3.0	+12.8	50.5	5.8	+10.9	-1.3	9.6	+9.1	81.8	12.6	+8.2	+7.2
Ice cream	13.2	+6.9	44.8	28.9	+4.0	-2.1	38.2	+5.0	83.5	46.5	+5.3	+1.4
Chocolate	18.8	+2.2	49.6	38.0	+1.6	+0.0	67.4	+1.6	72.7	95.6	+3.0	+3.0
Nutritional products ^(Note)	12.0	+15.4	49.6	24.6	+11.2	+1.4	38.6	+9.2	78.1	50.3	+8.7	+1.7
Sports nutrition	4.3	+48.5	51.9	8.7	+32.4	+4.3	12.7	+33.3	85.9	16.2	+30.4	+9.3

Results -- FYE March 2016					
H1 (Q1-Q2)	YoY Change	H2 (Q3-Q4)	YoY Change	Full-year	YoY Change
%	%	%	%	%	%
42.8	+6.4	40.3	+6.3	83.1	+6.4
39.0	+6.0	37.1	+6.7	76.1	+6.4
45.6	+17.0	61.1	+26.7	106.7	+22.4
56.1	+1.3	52.8	+1.7	108.9	+1.5
29.9	+4.6	27.4	+3.8	57.4	+4.2
16.3	+1.0	18.4	+5.0	34.8	+3.1
5.8	+10.9	6.7	+5.9	12.6	+8.2
28.9	+4.0	17.5	+7.5	46.5	+5.3
38.0	+1.6	57.5	+3.9	95.6	+3.0
24.6	+11.2	25.6	+6.4	50.3	+8.7
8.7	+32.4	7.5	+28.2	16.2	+30.4

Note: Nutritional products includes infant formula and enteral formula.

2. Pharmaceuticals Segment (Non-consolidated)

(Billions of yen)

FYE March 2017		Q1		Q1-Q2		Q1-Q3		Full-year	
		YoY Change	H1 Plan Achievement Rate	YoY Change	vs. H1 Plan	YoY Change	Full-year Plan Achievement Rate	YoY Change	vs. Full-year Plan
		%	%	%	%	%	%	%	%
Ethical pharma ceuticals	Total brand name drugs	11.3	-11.3	43.9					
	MEIACT	1.9	-36.6	41.8					
	ORAPENEM	0.4	-12.3	48.3					
	REFLEX	4.6	+4.1	49.1					
	Total generic drugs	9.7	-4.4	45.3					
	AMLODIPINE	1.0	-20.4	40.6					
	DONEPEZIL	0.6	-20.8	38.3					
(By field)	Total infectious diseases*	8.0	-16.7	47.6					
	Total CNS disorders*	8.1	+4.5	51.3					
Export	MEIACT	0.6	-28.9	60.5					
Agric.	ORYZEMATE	0.3	-2.6	79.2					

Plan -- FYE March 2017					
H1 (Q1-Q2)	YoY Change	H2 (Q3-Q4)	YoY Change	Full-year	YoY Change
%	%	%	%	%	%
25.8	+1.2	33.3	+20.5	59.2	+11.2
4.7	-22.2	5.1	-29.6	9.8	-26.2
0.9	+0.3	1.6	+15.8	2.5	+9.5
9.4	+1.8	10.9	+11.6	20.3	+6.8
21.4	+3.4	27.5	+23.4	48.9	+13.8
2.6	-3.4	3.0	+8.9	5.7	+2.8
1.8	+0.4	2.1	+19.8	3.9	+10.0
16.9	-12.2	19.8	-7.5	36.8	-9.7
15.9	-0.6	18.3	+9.9	34.3	+4.8
1.0	-36.1	1.1	+40.2	2.1	-9.5
0.4	+0.4	7.2	+17.7	7.6	+16.4

FYE March 2016		Q1		Q1-Q2		Q1-Q3		Full-year					
		YoY Change	H1 Plan Achievement Rate	YoY Change	vs. H1 Plan	YoY Change	Full-year Plan Achievement Rate	YoY Change	vs. Full-year Plan				
		%	%	%	%	%	%	%	%				
Ethical pharma ceuticals	Total brand name drugs	12.7	+12.5	49.7	25.5	+9.6	-0.6	40.7	+4.7	75.6	53.2	+3.9	-1.4
	MEIACT	3.1	+0.4	52.6	6.1	+3.1	+2.4	10.3	-1.4	80.3	13.4	-2.4	+3.6
	ORAPENEM	0.5	+43.1	49.3	0.9	+31.0	-10.7	1.7	+16.5	71.3	2.3	+12.5	-4.9
	REFLEX	4.4	+50.1	48.2	9.2	+30.7	+0.4	14.3	+21.0	73.3	19.0	+20.5	-2.7
	Total generic drugs	10.1	+15.6	46.4	20.7	+16.9	-5.4	32.8	+15.8	74.4	43.0	+14.3	-2.5
	AMLODIPINE	1.3	+12.2	48.2	2.7	+13.1	-2.0	4.3	+12.2	76.2	5.5	+8.6	-1.8
	DONEPEZIL	0.8	+11.2	39.6	1.7	+10.0	-18.5	2.7	+9.8	65.2	3.5	+6.1	-17.4
(By field)	Total infectious diseases*	9.6	+8.0	51.8	19.3	+9.0	+3.2	31.4	+5.1	78.6	40.7	+4.3	+2.0
	Total CNS disorders*	7.8	+23.8	47.7	16.0	+16.7	-2.1	25.0	+12.8	73.9	32.8	+12.2	-3.3
Export	MEIACT	0.8	+162.7	127.3	1.5	+111.6	+134.3	2.2	+77.7	77.5	2.4	+82.3	-15.7
Agric.	ORYZEMATE	0.3	+62.7	74.1	0.4	+50.6	-9.3	1.2	+39.9	16.7	6.6	+5.1	-13.7

Results -- FYE March 2016					
H1 (Q1-Q2)	YoY Change	H2 (Q3-Q4)	YoY Change	Full-year	YoY Change
%	%	%	%	%	%
25.5	+9.6	27.6	-0.8	53.2	+3.9
6.1	+3.1	7.2	-6.7	13.4	-2.4
0.9	+31.0	1.3	+2.6	2.3	+12.5
9.2	+30.7	9.7	+12.2	19.0	+20.5
20.7	+16.9	22.3	+11.9	43.0	+14.3
2.7	+13.1	2.8	+4.6	5.5	+8.6
1.7	+10.0	1.7	+2.4	3.5	+6.1
19.3	+9.0	21.4	+0.5	40.7	+4.3
16.0	+16.7	16.7	+8.1	32.8	+12.2
1.5	+111.6	0.8	+44.7	2.4	+82.3
0.4	+50.6	6.1	+2.6	6.6	+5.1

Note: Total for brand name and generic drugs in the infectious diseases and the CNS disorders fields

8. Other

1. (Ref.) Net Sales of Exports and Foreign Consolidated Group Companies

(Billions of yen)

FYE March 2017	Q1		Q1-Q2		Q1-Q3		Full-year	
	YoY Change	H1 Plan Achievement Rate	YoY Change	vs. H1 Plan	YoY Change	Full-year Plan Achievement Rate	YoY Change	vs. Full-year Plan
	%	%	%	%	%	%	%	%
Food segment	8.8	+12.0	43.0					
Pharmaceuticals segment	9.0	-15.8	41.4					

Plan -- FYE March 2017					
H1 (Q1-Q2)	YoY Change	H2 (Q3-Q4)	YoY Change	Full-year	YoY Change
	%		%		%
20.4	+16.0	24.3	+17.6	44.8	+16.9
21.9	+5.3	24.1	+14.4	46.1	+9.9

FYE March 2016	Q1		Q1-Q2		Q1-Q3		Full-year	
	YoY Change	H1 Plan Achievement Rate	YoY Change	vs. H1 Plan	YoY Change	Full-year Plan Achievement Rate	YoY Change	vs. Full-year Plan
	%	%	%	%	%	%	%	%
Food segment	7.8	+21.4	45.4	+1.0	28.3	+39.6	73.0	-1.3
Pharmaceuticals segment	10.7	+176.2	52.2	+0.9	30.3	+129.6	72.4	+0.2

Results -- FYE March 2016					
H1 (Q1-Q2)	YoY Change	H2 (Q3-Q4)	YoY Change	Full-year	YoY Change
	%		%		%
17.6	+34.6	20.7	+27.0	38.3	+30.4
20.8	+150.9	21.0	+34.8	41.9	+75.1

Note : Net sales for the parent company export business and net sales (after elimination) from international subsidiaries subject to the scope of consolidation are indicated as above reference information.

2. List of New Products Under Development

Stage	Name	Type	Efficacy Classification	Notes
Approved	SYCREST SUBLINGUAL TABLETS (asenapine)	Sublingual	Antipsychotic	Approved on March 28, 2016
Applied	Depromel SME3110 (fluvoxamine)	Oral	Selective serotonin reuptake inhibitor (SSRI) (Pediatric OCD) (Additional indications)	Co-development: AbbVie G.K.
Phase III	ME2112 (ziprasidone)	Oral	Antipsychotic	In-license: RaQualia Pharma Inc.
Phase II/III	ME2125 (safinamide)	Oral	Anti-Parkinson's Disease	In-license: Newron Pharmaceutical S.p.A. (Italy)
Phase II (International collaborative clinical trial)	SP-02L (darinaparsin)	Injection	Relapsed and refractory peripheral T-cell lymphoma (PTCL)	In-license: Solasia Pharma K.K.
Phase II	REFLEX Org3770 (mirtazapine)	Oral	Fibromyalgia treatment (Additional indications)	In-license: MSD K.K.
Phase II (Overseas)	ME1111	Topical	Antionychomycosis	Meiji Seika Pharma Co., Ltd.
Phase I	DMB-3111	Injection	Breast cancer/Gastric cancer (Biosimilar)	Co-development: Dong-A Socio Holdings Co., Ltd. (Korea)
Phase I (Overseas)	ME1100 (arbakacin)	Inhalation	Hospital Acquired Bacterial Pneumonia/ Ventilator Associated Bacterial Pneumonia treatment (HABP/VABP)	Meiji Seika Pharma Co., Ltd.
	OP0595	Injection	β-lactamase inhibitor	Licensed out to F. Hoffman-La Roche (Switzerland)